Background: Patients at the end of life often receive numerous medications for symptom management. In contrast to all other clinical situations, the aim of pharmacotherapy is strictly focused on quality of life.
Objective: The primary aims of this study were to assess the potential for drug-drug interactions (DDIs) in patients at the very end of life by identifying drug combinations and risk factors associated with a high risk of DDIs; and evaluate the clinical relevance of the potential DDIs in this unique patient population. Secondary objectives were to increase prescriber awareness and to derive a comprehensive framework for physicians to minimize DDIs in this specific setting of end-of-life care.
Materials and Methods: Charts of 364 imminently dying inpatients of two hospices were reviewed retrospectively. Drugs prescribed during the last 2 weeks of life were screened for DDIs by the electronic database of the Federal Union of German Associations of Pharmacists, which classifies DDIs by therapeutic measures required to reduce possible adverse events according to the ORCA system (OpeRational ClAssification of Drug Interactions).
Results: Potential DDIs were detected in 223 patients (61%). In a multivariate analysis, polypharmacy was the major predictor for DDIs (odds ratio 1.5, 95% CI 1.4, 1.6). The drugs most commonly involved in therapeutically rel evant potential DDIs were antipsychotics, antiemetics (e.g. metoclopramide, antihistamines), antidepressants, insulin, glucocorticoids, cardiovascular drugs and, in particular, NSAIDs. The most prevalent potential adverse effects were pharmacodynamically additive anticholinergic, antidopaminergic, cardiac (QT interval prolongation) and NSAID-associated toxicity (e.g. gastrointestinal, renal).
Conclusion: In the context of end-of-life care, the clinical relevance of DDIs differs from other clinical settings. Most DDIs can be prevented if the prescribing physician considers a few therapeutic principles. Specifically, this concerns the awareness of futile and high-risk medications, as well as rational alternatives.
Palliative Care Clopidogrel Pregabalin Dipyrone Hospice Care
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
This study was supported by an unrestricted research grant from Mundipharma. The scientific work of the Department of Palliative Medicine, University Clinic of Cologne, is supported by the Federal Ministry for Education and Science (BMBF 01KN1106). The clinical and academic activities of the Department of Palliative Medicine, University Clinic of Cologne, are substantially supported by the German Cancer Aid (Deutsche Krebshilfe e.V.).
The authors declare no conflicts of interest.
The authors would like to thank the Managing Directors of the two hospices, Verena Tophofen (“Haus Erftaue”, Erftstadt, Germany) and Sebastian Roth (“Stationäres Hospiz im Waldkrankenhaus”, Bad Godesberg, Germany) for their kind and helpful cooperation that made this study possible.
Riechelmann RP, Tannock IF, Wang L, et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007; 99(8): 592–600PubMedCrossRefGoogle Scholar
van Leeuwen RW, Swart EL, Boom FA, et al. Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method. BMC Cancer 2010; 10: 679PubMedCrossRefGoogle Scholar
Girre V, Arkoub H, Puts MT, et al. Potential drug interactions in elderly cancer patients. Crit Rev Oncol Hematol 2011; 78(3): 220–6PubMedCrossRefGoogle Scholar
van Leeuwen RW, Swart EL, Boven E, et al. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol 2011; 22(10): 2334–41PubMedCrossRefGoogle Scholar
Lal LS, Zhuang A, Hung F, et al. Evaluation of drug interactions in patients treated with antidepressants at a tertiary care cancer center. Support Care Cancer 2012; 20(5): 983–9PubMedCrossRefGoogle Scholar
Bernard SA, Bruera E. Drug interactions in palliative care. J Clin Oncol 2000; 18(8): 1780–99PubMedGoogle Scholar
Gaertner J, Ruberg K, Schlesiger G, et al. Drug interactions in palliative care: it’s more than cytochrome P450. Palliat Med. Epub 2011 Jul 7Google Scholar
Riechelmann RP, Zimmermann C, Chin SN, et al. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manage 2008; 35(5): 535–43PubMedCrossRefGoogle Scholar
Kohler GI, Bode-Boger SM, Busse R, et al. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000; 38(11): 504–13PubMedGoogle Scholar
Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289(13): 1652–8PubMedCrossRefGoogle Scholar
Miranda V, Fede A, Nobuo M, et al. Adverse drug reactions and drug interactions as causes of hospital admission in oncology. J Pain Symptom Manage 2011; 42(3): 342–53PubMedCrossRefGoogle Scholar
Holmes HM, Hayley DC, Alexander GC, et al. Reconsidering medication appropriateness for patients late in life. Arch Intern Med 2006; 166(6): 605–9PubMedCrossRefGoogle Scholar
Riechelmann RP, Krzyzanowska MK, Zimmermann C. Futile medication use in terminally ill cancer patients. Support Care Cancer 2009; 17(6): 745–8PubMedCrossRefGoogle Scholar
Fede A, Miranda M, Antonangelo D, et al. Use of un necessary medications by patients with advanced cancer: cross-sectional survey. Support Care Cancer 2011; 19(9): 1313–8PubMedCrossRefGoogle Scholar
Harrington CJ, Zaydfudim V. Buprenorphine maintenance therapy hinders acute pain management in trauma. Am Surg 2010;76(4): 397–9PubMedGoogle Scholar
Preston KL, Bigelow GE, Liebson IA. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers. J Pharma col Exp Ther 1988; 246(2): 441–8Google Scholar
Oifa S, Sydoruk T, White I, et al. Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 post-operative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery. Clin Ther 2009; 31(3): 527–41PubMedCrossRefGoogle Scholar
Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009; 13(3): 219–30PubMedCrossRefGoogle Scholar
Lertxundi U, Peral J, Mora O, et al. Antidopaminergic therapy for managing comorbidities in patients with Parkinson’s disease. Am J Health Syst Pharm 2008; 65(5): 414–9PubMedCrossRefGoogle Scholar
Cuisset T, Frere C, Quilici J, et al. Comparison of omepra-zole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009; 54(13): 1149–53PubMedCrossRefGoogle Scholar
Perucca E. Clinically relevant drug interactions with anti-epileptic drugs. Br J Clin Pharmacol 2006; 61(3): 246–55PubMedCrossRefGoogle Scholar
Lyseng-Williamson KA. Levetiracetam: a review of its use in epilepsy. Drugs 2011; 71(4): 489–514PubMedGoogle Scholar
Semel D, Murphy TK, Zlateva G, et al. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Fam Pract 2010; 11:85PubMedCrossRefGoogle Scholar
Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000; 47(2): 219–33PubMedCrossRefGoogle Scholar
Shah RR. Drug-induced QT interval prolongation: regulatory perspectives and drug development. Ann Med 2004; 36 Suppl. 1:47–52PubMedCrossRefGoogle Scholar
Shephard DA. Principles and practice of palliative care. Can Med Assoc J 1977; 116(5): 522–6PubMedGoogle Scholar
Wilcock A, Beattie JM. Prolonged QT interval and metha-done: implications for palliative care. Curr Opin Support Palliat Care 2009; 3(4): 252–7PubMedCrossRefGoogle Scholar
Flockhart DA, Desta Z, Mahal SK. Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions. Clin Pharmacokinet 2000; 39(4): 295–309PubMedCrossRefGoogle Scholar
Glare PA, Dunwoodie D, Clark K, et al. Treatment of nausea and vomiting in terminally ill cancer patients. Drugs 2008; 68(18): 2575–90PubMedCrossRefGoogle Scholar
Davis MP, Hallerberg G. A systematic review of the treat ment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manage 2010; 39(4): 756–67PubMedCrossRefGoogle Scholar
Wilens TE, Stern TA, O’Gara PT. Adverse cardiac effects of combined neuroleptic ingestion and tricyclic antidepressant overdose. J Clin Psychopharmacol 1990; 10(1): 51–4PubMedCrossRefGoogle Scholar
Ness J, Hoth A, Barnett MJ, et al. Anticholinergic medications in community-dwelling older veterans: prevalence of anticholinergic symptoms, symptom burden, and adverse drug events. Am J Geriatr Pharmacother 2006; 4(1): 42–51PubMedCrossRefGoogle Scholar
Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 2001; 62 Suppl. 21: 11–4PubMedGoogle Scholar
Candy M, Jones L, Williams R, et al. Psychostimulants for depression. Cochrane Database Syst Rev 2008; (2): CD006722PubMedGoogle Scholar
Mishra S, Bhatnagar S, Nirvani Goyal G, et al. A comparative efficacy of amitriptyline, gabapentin, and prega-balin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am J Hosp Palliat Care 2012; 29(3): 177–82PubMedCrossRefGoogle Scholar
Reilly JG, Ayis SA, Ferrier IN, et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355(9209): 1048–52PubMedCrossRefGoogle Scholar
Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114(9): 735–40PubMedCrossRefGoogle Scholar
Simon ST, Bausewein C. Management of refractory breath-lessness in patients with advanced cancer. Wien Med Wochenschr 2009; 159(23-24): 591–8PubMedCrossRefGoogle Scholar
Shih A, Jackson KC. Role of corticosteroids in palliative care. J Pain Palliat Care Pharmacother 2007; 21(4): 69–76PubMedCrossRefGoogle Scholar
Christensen RC, Byerly MJ. Mandibular dystonia asso ciated with the combination of sertraline and metoclopramide [letter]. J Clin Psychiatry 1996; 57(12): 596PubMedCrossRefGoogle Scholar
Fisher AA, Davis MW. Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. Ann Pharmacother 2002; 36(1): 67–71PubMedCrossRefGoogle Scholar
Jackson N, Doherty J, Coulter S. Neuropsychiatric complications of commonly used palliative care drugs. Postgrad Med J 2008; 84(989): 121–6; quiz 5PubMedCrossRefGoogle Scholar
Vandraas KF, Spigset O, Mahic M, et al. Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly. Eur J Clin Pharmacol 2010; 66(8): 823–9PubMedCrossRefGoogle Scholar
Schug SA, Manopas A. Update on the role of non-opioids for postoperative pain treatment. Best Pract Res Clin Anaesthesiol 2007; 21(1): 15–30PubMedCrossRefGoogle Scholar
McNicol E, Strassels SA, Goudas L, et al. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev 2005; (1): CD005180PubMedGoogle Scholar
Wilcock A, Thomas J, Frisby J, et al. Potential for drug interactions involving cytochrome P450 in patients at tending palliative day care centres: a multicentre audit. Br J Clin Pharmacol 2005; 60(3): 326–9PubMedCrossRefGoogle Scholar
Haddad A, Davis M, Lagman R. The pharmacological im portance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Support Care Cancer 2007; 15(3): 251–7PubMedCrossRefGoogle Scholar
Regnard C, Hunter A. Increasing prescriber awareness of drug interactions in palliative care. J Pain Symptom Manage 2005; 29(3): 219–21PubMedCrossRefGoogle Scholar
O’Connor M, Pugh J, Jiwa M, et al. The palliative care interdisciplinary team: where is the community pharmacist?. J Palliat Med 2011; 14(1): 7–11PubMedCrossRefGoogle Scholar
Borgsteede SD, Rhodius CA, De Smet PA, et al. The use of opioids at the end of life: knowledge level of pharmacists and cooperation with physicians. Eur J Clin Pharmacol 2011; 67(1): 79–89PubMedCrossRefGoogle Scholar